Zacks Rating on Sunesis Pharmaceuticals (SNSS)

Sunesis Pharmaceuticals (SNSS) : 3 analysts are covering Sunesis Pharmaceuticals (SNSS) and their average rating on the stock is 1.67, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Shares of Sunesis Pharmaceuticals, Inc. rose by 24.72% in the last five trading days and 50% for the last 4 weeks. Sunesis Pharmaceuticals, Inc. is up 62.84% in the last 3-month period. Year-to-Date the stock performance stands at -13.09%. Sunesis Pharmaceuticals (NASDAQ:SNSS): On Tuesdays trading session , Opening price of the stock was $0.77 with an intraday high of $0.804. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.76. However, the stock managed to close at $0.78, a loss of 2.51% for the day. On the previous day, the stock had closed at $0.8001. The total traded volume of the day was 291,066 shares.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.